Voucher
Scheme
Phenomics Australia offers a voucher scheme to facilitate and encourage access to one or more Phenomics Australia facilities. This scheme is intended to further reduce the cost of access to a specific capability.
Pipeline Accelerator - Voucher Scheme
Access the Pipeline
Through the National Collaborative Research Infrastructure Strategy (NCRIS) program, Phenomics Australia and Therapeutic Innovation Australia (TIA) seamlessly support a network of national research infrastructure to address the medical products challenge in the 2021 National Research Infrastructure (NRI) Roadmap. We collectively offer academic researchers and SMEs access to a diverse range of Australian translational medical research capabilities, from the molecular basis of health and disease through to clinical trials.
To encourage access to these capabilities, TIA has developed the Pipeline Accelerator, a voucher-style scheme that supports the cost of access to a broad range of advanced capabilities. In this Pipeline Accelerator round, Phenomics Australia is partnering with TIA to expand the portfolio of services and expertise enabling medical research discovery and translation.
This scheme aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.
Refer to the guidelines for information on eligibility, funding levels, co-investment expectations, as well as the application and funding process. All applicants are required to complete and submit the applications online. The link to the application form can be found in the guideline document. We strongly advise you to develop your application on the provided template as the online form cannot be saved and retrieved at a later date.
Applications close on 13th October 2023, 5pm (AEST).
Voucher scheme documents
Please click on buttons below to download the appropriate documents for the current round.
Voucher Scheme Webinars
If you have any questions regarding our voucher schemes, you are invited to check our virtual information session which was held on the 14th of March 2023, 12pm AEST
More information
For further information about the voucher scheme, please contact:
Pipeline Accelerator FAQs
Search for an answer here
Pipeline Accelerator Outcomes
All awarded Pipeline Accelerator projects will be listed here.
Round | Lead applicant | Affiliation | Project title | Phenomics Australia node ( Capability provider) |
|---|---|---|---|---|
22_23_Round 2 | Prof James Hudson | QIMR Berghofer | Development of an epicardial lineage tracing human pluripotent stem cell line to identify new cardiac therapeutics | Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility |
22_23_Round 2 | Dr Graham A. Mackay | The University of Melbourne | MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation | Victorian Centre for Functional Genomics |
22_23_Round 2 | Dr Brett McKinnon | The University of Queensland | High throughput screening of micro-organoids for assessing heterogeneity and precision medicine potential in endometriosis | Victorian Centre for Functional Genomics |
22_23_Round 2 | Dr Zhian Chen | The University of Queensland | The role of ferroptosis and oxidative stress in regulating immunity | Monash Genome Modification Platform |
22_23_Round 2 | Dr Svenja Pachernegg | Murdoch Children's Research Institute | Using iPSCs to determine the role of NR2F2 in ovarian development and 46,XX sex reversal | Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility |
22_23_Round 2 | Dr Ada Koo | The University of Melbourne | Developing transcriptomic and morphological profiling of macrophages to mine the microbiome | Victorian Centre for Functional Genomics |
22_23_Round 2 | Dr Alexander Nicholas Combes | Monash University | New therapeutic strategies and targets to suppress acute kidney injury | Victorian Centre for Functional Genomics and Monash Functional Genomics Platform |
22_23_Round 2 | Dr Simon Preston | Anaxis Pharma Pty Ltd | Evaluating human organoids as model systems in drug development | Monash Organoid Program |
22_23_Round 2 | A/Prof Edwina McGlinn | Monash University | Tick tock, tick tock… Mechanisms pacing the Hox clock | Monash Functional Genomics Platform |
Therapeutic Innovation Australia (TIA) is a national consortium of translational research infrastructure with a focus on the development of new therapeutic products such as biologics and vaccines, cell and gene therapies as well as small molecule pharmaceuticals. More information here.